International Journal of

Immunology and ImmunotherapyISSN: 2378-3672


 Open Access DOI:10.23937/2378-3672/1410039

Transfer Factors or Dialyzable leukocyte Extracts as Immunomodulating Peptides: A Conceptual Review on Broad Spectrum of Therapeutic Areas, Immunologic and Clinical Responses, Trends and Perspectives

Dina Tulina, Mike KS Chan, Michele WBF and Shing Yi Pan

Article Type: Research Article | First Published: November 04, 2019

Immune Modulating Peptides (IMP) discussed in literature as a universal immunocorrectors with wide areas of usage which balance the immune system without causing global immune suppression or overreaction. The present article aim is to review the effect and drawbacks of IMPs in form of Dialyzable leukocyte Extracts (DLE) or Transfer Factors (TF) during and following chemotherapy, radiotherapy, drugs interactions, cancer response and clinical outcomes in different cases of cancers such as metastat...

 Open Access DOI:10.23937/2378-3672/1410038

The Role of Genetics Mutations in Genes PORCN, TWIST2, HCCS in Goltz Syndrome

Shahin Asadi and Mahsa Jamali

Article Type: Review Article | First Published: August 26, 2019

Goltz syndrome (focal skin hypoplasia) is a genetic disorder that primarily affects the skin, skeletal system, eyes and face. People with Goltz syndrome have birth defects. These disorders include very thin skin veins (skin hypoplasia), pink yellow nodules, subcutaneous fat, lack of upper skin layers (aplasia cutis), small clusters of superficial skin vessels (telangiectasia), and veins in dark skin Or bright. Goltz syndrome is caused by mutation genes PORCN, TWIST2, HCCS. Goltz syndrome (focal ...

 Open Access DOI:10.23937/2378-3672/1410037

Rituximab Modifies Peripheral Blood Mononuclear Cells Immune Responses

Meir-Djaldetti, MD, Chyia-Leibovitch, MD, Esther-Ganelin-Cohen, MD, PhD and Hanna-Bessler, PhD

Article Type: Research Article | First Published: August 26, 2019

Rituximab, the monoclonal antibody against B lymphocyte protein CD20, is a major asset for treatment of diseases in which B CD20 cells are the foremost etiologic culprit. Based on observations that rituximab is capable to modulate immune responses the question if the drug may affect the capacity of human peripheral blood mononuclear cells (PBMC) for cytokine production was posed. The discovery of rituximab, a monoclonal antibody against B lymphocyte membrane protein CD20, contributed greatly to ...

 Open Access DOI:10.23937/2378-3672/1410036

S-Nitrosoglutathione Modulates Expansion of Activated CD4CD25 Cells by Apoptosis under Inflammatory Condition

Subhajit Dasgupta

Article Type: Research Article | First Published: June 08, 2019

The regulation checkpoints of CD4CD25 expansion in presence and absence of transcription factor FOXP3 are critical to maintain balance between inflammatory TH17 and anti-inflammatory FOXP3CD4CD25 Treg cells. We investigated impact of potent inflammatory mediator nitric oxide NO(.) on commitment of normal spleen T cells following activation. The single cell suspension of healthy C57BL/6 mice splenic CD4 cells was stimulated by plate-bound antiCD3/antiCD28 antibodies in presence of cytokine cockta...

 Open Access DOI:10.23937/2378-3672/1410035

Cancer Immunotherapy Therapeutic Manipulation of the CD8-HLA Class I Interaction: Potential and Challenges

P Savage

Article Type: REVIEW ARTICLE | First Published: February 23, 2019

The interaction between CD8 and HLA class I is largely monomorphic and of low affinity. Previous HLA mutation studies have indicated that manipulation of the affinity of this interaction can have dramatic biological effects. Reductions in CD8-HLA class I affinity can lead to inhibition of T cell mediated target cell killing, whilst modest affinity increases lead to enhanced target cell killing whilst retaining antigenic specificity. Here it is shown that target cells bearing a high affinity chim...

Volume 6
Issue 1